Recombinant human ErbB-3 /HER3 Protein, His Tag, 100µg

Background
ErbB3, also known as Her3 (human epidermal growth factor receptor 3), is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound glycoprotein has a neuregulin binding domain but has not an active kinase domain. It therefore can bind the ligand but cannot mediate the intracellular signal transduction through protein phosphorylation.
However, it does form heterodimers with ErbB2 or other EGFR members responsible for tyrosine phosphorylation to give a receptor complex and initiate the related pathway, which lead to cell proliferation or differentiation. Overexpression of this protein has been reported in numerous cancers, including prostate, bladder, and breast tumors. This protein has different isoforms derived from alternative splicing variants, and among which, the secreted isoform lacking the intermembrane region modulates the activity of membrane-bound form.[1-6]

Source
Recombinant Human ErbB3, His Tag (ER3-H5223) is expressed from human 293 cells (HEK293). It contains AA Ser 20 - Thr 643 (Accession # P21860-1).
Predicted N-terminus: Ser 20

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 70.5 kDa. The protein migrates as 70-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rhErbB3 by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "ERBB3-Activating Mutations in Small Bowel Adenocarcinomas
Cabel, Aparicio, Bieche et al
JCO Precis Oncol (2018) 2, 1-9
(2) "Identification of a DNA repair 9-gene signature for the overall survival prediction of pancreatic cancer
Huang, Mao, Sun
Ann Diagn Pathol (2022) 57, 151883
(3) "Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
Campbell, Ruiz-Saenz, Zhang et al
Cell Rep (2022) 38 (5), 110285
Showing 1-3 of 2243 papers.

Citations

(1) "EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors"
Authors: Capone E , Lattanzio R , Gasparri F , et al.
Journal: Pharmaceutics 2021
Application: ELISA
(2) "STABILIZED CHIMERIC FABS"
Authors: Urosev Dunja, et al.
Journal: US20200308270A1 2020
Application: SPR
(3) "Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto"
Authors: J Rohloff et al.
Journal: US9938314B2 2018
Application: SELEX
(4) "EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma"
Authors: Capone E, et al.
Journal: J Control Release 2018
Application: ELISA
(5) "Efficient generation of single domain antibodies with high affinities and enhanced thermal stabilities"
Authors: Shinozaki N, et al.
Journal: Sci Rep 2017
Application: Rabbit immunization